ESMO ASIA | 翰森制药Risvutatug Rezetecan( HS-20093)治疗NSCLC的Ⅰ期研究结果亮相

翰森制药
Dec 17, 2025

-在局部晚期或转移性非小细胞肺癌(NSCLC)患者中,Risvutatug Rezetecan给药剂量8.0 和10.0 mg/kg每3周一次,表现出令人振奋的抗肿瘤活性,尤其是在驱动基因(AGA)阴性的非鳞状NSCLC中。- Risvutatug Rezetecan的安全性可控,符合其作用机制。10.0 mg/kg剂量组中≥3级TRAEs和剂量降低的发生率高于8.0 mg/kg剂量组。-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10